Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
作者信息
Antinori Spinello, Bonazzetti Cecilia, Gubertini Guido, Capetti Amedeo, Pagani Cristina, Morena Valentina, Rimoldi Sara, Galimberti Laura, Sarzi-Puttini Piercarlo, Ridolfo Anna Lisa
机构信息
Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy.
Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy.
出版信息
Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5.
Abstract
摘要
相似文献
1
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?托珠单抗治疗新型冠状病毒肺炎细胞因子风暴综合征：念珠菌血症风险增加？
Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5.
2
Cytokine storm syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子风暴综合征
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.
3
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?COVID-19 与抗 MDA5 综合征的相似之处：我们能从中吸取哪些经验以改善治疗？
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01618-2020. Print 2020 Sep.
4
To immunosuppress: whom, when and how? That is the question with COVID-19.进行免疫抑制：对象是谁、何时进行以及如何进行？这就是新冠病毒病面临的问题。
Ann Rheum Dis. 2020 Sep;79(9):1129-1131. doi: 10.1136/annrheumdis-2020-218694. Epub 2020 Aug 4.
5
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.英夫利昔单抗可将新冠肺炎危重症患者的死亡率从35%降至14%：或许有一些潜在混杂因素需要考虑。
Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7.
6
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.为何适时进行的抗白细胞介素6治疗可能对重症COVID-19感染有益。
Autoimmun Rev. 2020 Jul;19(7):102563. doi: 10.1016/j.autrev.2020.102563. Epub 2020 May 5.
7
Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?针对危重症 COVID-19 患者的细胞因子风暴综合征，血液净化疗法是否有作用？
Ren Fail. 2020 Nov;42(1):483-488. doi: 10.1080/0886022X.2020.1764369.
8
Is the HScore useful in COVID-19?HScore在新冠病毒疾病（COVID-19）中有用吗？
Lancet. 2020 May 16;395(10236):e83. doi: 10.1016/S0140-6736(20)31057-6. Epub 2020 May 5.
9
[Progress in research on cytokine storm].[细胞因子风暴的研究进展]
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Nov 6;54(11):1300-1304. doi: 10.3760/cma.j.cn112150-20200529-00799.
10
Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19.用于治疗新型冠状病毒肺炎细胞因子风暴的抗白细胞介素-6单克隆抗体
Ann Thorac Med. 2020 Jul-Sep;15(3):171-173. doi: 10.4103/atm.ATM_286_20. Epub 2020 Jun 18.
引用本文的文献
1
Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review.重症 COVID-19 患者侵袭性念珠菌合并感染：范围综述
Pathogens. 2025 May 10;14(5):466. doi: 10.3390/pathogens14050466.
2
Can the Early Warning Score (ANDC) Predict Tocilizumab Efficacy in Patients with COVID-19 Cytokine Storm?早期预警评分（ANDC）能否预测托珠单抗对COVID-19细胞因子风暴患者的疗效？
Eur J Rheumatol. 2025 Apr 16;12(1):1-6. doi: 10.5152/eurjrheum.2025.24048.
3
Characterization of COVID-19-Associated Candidemia Among Burn Patients.烧伤患者中与COVID-19相关的念珠菌血症的特征
J Clin Lab Anal. 2025 May;39(10):e70031. doi: 10.1002/jcla.70031. Epub 2025 Apr 8.
4
Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.COVID-19 住院和重症患者并发念珠菌血症：系统评价和荟萃分析。
Mycoses. 2024 Oct;67(10):e13798. doi: 10.1111/myc.13798.
5
Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.托珠单抗在重症新型冠状病毒肺炎中的治疗作用；对当前证据的最新综合综述
Arch Acad Emerg Med. 2024 May 9;12(1):e47. doi: 10.22037/aaem.v12i1.2217. eCollection 2024.
6
Risk analysis of candidemia and its effect on mortality in COVID 19 and non COVID 19 patients.COVID-19患者和非COVID-19患者念珠菌血症的风险分析及其对死亡率的影响。
Iran J Microbiol. 2024 Apr;16(2):236-242. doi: 10.18502/ijm.v16i2.15357.
7
Interleukin inhibitors and the associated risk of candidiasis.白细胞介素抑制剂及相关的念珠菌病发病风险。
Front Immunol. 2024 Mar 28;15:1372693. doi: 10.3389/fimmu.2024.1372693. eCollection 2024.
8
Radiological features of COVID-19-associated mucormycosis: A report of 36 cases along with a literature review.新型冠状病毒肺炎相关毛霉菌病的影像学特征：36例报告并文献复习
Clin Case Rep. 2023 Nov 20;11(11):e8154. doi: 10.1002/ccr3.8154. eCollection 2023 Nov.
9
Bloodstream Infections in Intensive Care Unit during Four Consecutive SARS-CoV-2 Pandemic Waves.连续四波新冠疫情期间重症监护病房的血流感染
Antibiotics (Basel). 2023 Sep 14;12(9):1448. doi: 10.3390/antibiotics12091448.
10
Invasive Candidiasis in Adult Patients with COVID-19: Results of a Multicenter Study in St. Petersburg, Russia.俄罗斯圣彼得堡成年新冠肺炎患者侵袭性念珠菌病：一项多中心研究结果
J Fungi (Basel). 2023 Sep 14;9(9):927. doi: 10.3390/jof9090927.
本文引用的文献
1
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
2
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.严重 COVID-19 中的细胞因子释放综合征：白细胞介素-6 受体拮抗剂托珠单抗可能是降低死亡率的关键。
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
5
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.用于治疗类风湿性关节炎的白细胞介素-6抑制剂：全面综述
Mod Rheumatol. 2019 Mar;29(2):258-267. doi: 10.1080/14397595.2018.1546357. Epub 2019 Jan 3.
6
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.托珠单抗治疗类风湿关节炎患者严重感染的风险因素：法国 REGATE 注册研究。
Rheumatology (Oxford). 2017 Oct 1;56(10):1746-1754. doi: 10.1093/rheumatology/kex238.
7
Candidemia and invasive candidiasis in adults: A narrative review.成人念珠菌血症和侵袭性念珠菌病：一篇叙述性综述。
Eur J Intern Med. 2016 Oct;34:21-28. doi: 10.1016/j.ejim.2016.06.029. Epub 2016 Jul 7.
8
Integrated safety in tocilizumab clinical trials.将托珠单抗临床试验中的安全性整合。
Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1.
9
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.托珠单抗治疗类风湿关节炎患者不良事件（包括严重感染）风险的系统文献回顾和荟萃分析：随机对照试验。
Rheumatology (Oxford). 2011 Mar;50(3):552-62. doi: 10.1093/rheumatology/keq343. Epub 2010 Nov 14.
10
Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice.白细胞介素-6缺陷小鼠对系统性念珠菌病易感性增加。
Med Mycol. 1999 Dec;37(6):419-26. doi: 10.1046/j.1365-280x.1999.00247.x.
Zotero 插件